Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Gynecologic Oncology

When Ovarian Cancer is Rare: Understanding Your Unique Diagnosis

At a Glance

Rare ovarian cancer is a group of uncommon tumors that behave and respond to treatment differently than standard ovarian cancer. Getting an exact diagnosis from an expert gynecologic pathologist is critical, as your subtype completely determines your prognosis and specific treatment plan.

Most of the information you find online—and even what many general doctors know—is about the most common type, called high-grade serous ovarian cancer (HGSOC) [1][2]. However, it is essential to understand that “ovarian cancer” is not just one disease; it is a collection of many different diseases that happen to start in the same part of the body [3][4]. Because your cancer is rare, it has its own “personality,” its own growth pattern, and its own specific treatments [5][6].

A Different Way of Thinking About Your Diagnosis

Rare ovarian cancers are generally divided into two main categories based on where the cancer cells began:

1. Rare Epithelial Tumors

These tumors start in the epithelium, which is the thin layer of tissue that covers the outside of the ovary. While the common HGSOC is also epithelial, these rare versions act very differently:

  • Low-Grade Serous Ovarian Cancer (LGSOC): This is distinct from the “high-grade” version. It often affects younger women and tends to grow more slowly (indolent) [7][3]. It is often driven by specific genetic pathways (like MAPK) rather than the aggressive mutations seen in common ovarian cancer [3][8].
  • Mucinous Ovarian Cancer: These tumors are characterized by cells that produce a jelly-like substance called mucus. They often require different surgical approaches and present unique treatment challenges [9][10].
  • Clear Cell Carcinoma: This type is often associated with endometriosis and has a unique molecular profile that may make it more resistant to traditional chemotherapy [11][10].

2. Non-Epithelial Tumors

These are much less common and start in other parts of the ovary:

  • Germ Cell Tumors: These begin in the cells that produce eggs. They are most common in teens and young adults [12].
  • Sex Cord-Stromal Tumors: These start in the structural tissue of the ovary that produces hormones like estrogen and progesterone. A well-known type is the Granulosa Cell Tumor. These can often be slow-growing and may be treated with hormonal therapies [12][13].

Redefining Your Prognosis

While the word “rare” sounds frightening, your long-term outlook (prognosis) depends entirely on your specific subtype [7][14]. Generalizing ovarian cancer survival statistics to your situation will likely be inaccurate.

  • Highly Curable Subtypes: Certain rare types, like germ cell tumors, have exceptionally high cure rates because they are incredibly sensitive to specific chemotherapy regimens, even if the disease has spread [12][15].
  • Slow-Growing Subtypes: Many rare types, like LGSOC or certain stromal tumors, grow much more slowly than common high-grade cancer, allowing for different management strategies [7].
  • Challenging Subtypes: Conversely, advanced Clear Cell or Mucinous carcinomas are often resistant to standard chemotherapy, presenting unique challenges that generally carry a more guarded prognosis than the common high-grade cancer [16][17]. This makes specialized, targeted care critical for these types.

Getting a correct diagnosis is the most important first step. This often requires a pathologist (a doctor who studies tissues) who has specific expertise in rare gynecologic cancers to ensure your cancer is classified correctly [4]. Knowing exactly which “rare” category you fall into is the key to unlocking the right treatment plan. You can learn more about how these subtypes behave in Why Rare Ovarian Cancer is Biologically Unique.

Common questions in this guide

What is the difference between rare and common ovarian cancer?
Common ovarian cancer typically refers to high-grade serous ovarian cancer. Rare ovarian cancers are different diseases that happen to start in the ovary but have unique growth patterns, genetic drivers, and treatment responses.
Are rare ovarian cancers curable?
The prognosis for rare ovarian cancer depends entirely on the specific subtype. Some rare types, like germ cell tumors, have exceptionally high cure rates, while others may grow slowly or require specialized, targeted treatments.
Why is it important to see a specialist for a rare ovarian cancer diagnosis?
Getting an exact diagnosis is critical because treatment depends entirely on your tumor type. A pathologist with specific expertise in rare gynecologic cancers can ensure your tumor is accurately classified so you get the most effective care.
What is a rare epithelial ovarian tumor?
Rare epithelial tumors start in the thin tissue covering the outside of the ovary but act differently than common types. Examples include low-grade serous ovarian cancer (LGSOC), mucinous ovarian cancer, and clear cell carcinoma.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific histological subtype and grade of my tumor?
  2. 2.How does the typical treatment for my specific type of cancer differ from common ovarian cancer?
  3. 3.Given the rarity of my diagnosis, how many patients with this specific subtype have you treated in the last year?
  4. 4.Should I seek a second opinion from a pathologist or oncologist who specializes specifically in rare gynecologic cancers?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer.

    Wang B, Chao S, Guo B

    Journal of clinical laboratory analysis 2022; (36(2)):e24165 doi:10.1002/jcla.24165.

    PMID: 34997982
  2. 2

    Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets.

    Voutsadakis IA

    Cancer management and research 2020; (12()):10423-10437 doi:10.2147/CMAR.S249540.

    PMID: 33116896
  3. 3

    Low-grade serous ovarian carcinoma: A comprehensive literature review.

    Goulding EA, Simcock B, McLachlan J, et al.

    The Australian & New Zealand journal of obstetrics & gynaecology 2020; (60(1)):27-33 doi:10.1111/ajo.13105.

    PMID: 31849044
  4. 4

    Clinicopathological Analysis of Ovarian Neoplasms at a Tertiary Care Teaching Institute of North Malabar: A Four-Year Retrospective Study.

    Ramakrishnan J, Singh MN, Paul B, Puthen Parambath S

    Cureus 2025; (17(1)):e77574 doi:10.7759/cureus.77574.

    PMID: 39958081
  5. 5

    The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.

    Cobb LP, Sun CC, Iyer R, et al.

    Gynecologic oncology 2020; (158(3)):653-658 doi:10.1016/j.ygyno.2020.06.498.

    PMID: 32709538
  6. 6

    Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer.

    Sama S, Rosqvist S, Savage T, et al.

    Gynecologic oncology reports 2024; (53()):101412 doi:10.1016/j.gore.2024.101412.

    PMID: 38779189
  7. 7

    Low-Grade Serous Carcinoma of the Ovary: The Current Status.

    Babaier A, Mal H, Alselwi W, Ghatage P

    Diagnostics (Basel, Switzerland) 2022; (12(2)) doi:10.3390/diagnostics12020458.

    PMID: 35204549
  8. 8

    Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian.

    Au-Yeung G, MacArthur E, Chan J, et al.

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2024; (44(3)):e431818 doi:10.1200/EDBK_431818.

    PMID: 39177646
  9. 9

    Prognostic significance of tumor laterality in advanced ovarian cancer.

    Yamada Y, Mabuchi S, Kawahara N, Kawaguchi R

    Obstetrics & gynecology science 2021; (64(6)):524-531 doi:10.5468/ogs.21176.

    PMID: 34517691
  10. 10

    Therapeutic advances and molecular insights in low-grade serous ovarian carcinoma.

    Kabirian R, Gaillard T, Bello-Roufai D, et al.

    Bulletin du cancer 2026; (113(4)):533-540 doi:10.1016/j.bulcan.2025.11.005.

    PMID: 41402140
  11. 11

    Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.

    Park HK, Ruterbusch JJ, Cote ML

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2017; (26(10)):1511-1518 doi:10.1158/1055-9965.EPI-17-0290.

    PMID: 28751475
  12. 12

    Differences in Characteristics and Outcomes Between Large-Cell Neuroendocrine Carcinoma of the Ovary and High-Grade Serous Ovarian Cancer: A Retrospective Observational Cohort Study.

    Pang L, Guo Z

    Frontiers in oncology 2022; (12()):891699 doi:10.3389/fonc.2022.891699.

    PMID: 35600342
  13. 13

    GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.

    Grisham R, Monk BJ, Van Nieuwenhuysen E, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2025; (35(11)):101832 doi:10.1136/ijgc-2024-005919.

    PMID: 39375168
  14. 14

    Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.

    Gockley A, Melamed A, Bregar AJ, et al.

    Obstetrics and gynecology 2017; (129(3)):439-447 doi:10.1097/AOG.0000000000001867.

    PMID: 28178043
  15. 15

    Multidisciplinary management of ovarian germ cell tumours-a single institutional study from India.

    Ganguly S, Gargy S, Basu A, et al.

    Ecancermedicalscience 2021; (15()):1290 doi:10.3332/ecancer.2021.1290.

    PMID: 34824613
  16. 16

    Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.

    Dong S, Yu F, Liu Y, et al.

    Ginekologia polska 2023; (94(10)):792-798 doi:10.5603/GP.a2022.0123.

    PMID: 36477777
  17. 17

    Primary mucinous ovarian cancer: options for surgery and chemotherapy.

    Kurnit KC, Frumovitz M

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(11)):1455-1462 doi:10.1136/ijgc-2022-003806.

    PMID: 36229081

This page provides educational information about rare ovarian cancer subtypes. It does not replace professional medical advice. Always consult a gynecologic oncologist for your specific diagnosis and treatment plan.

Get notified when new evidence is published on Rare ovarian cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.